Brief: FDA has granted 6-month additional exclusivity for Cariprazine in US, Richter says
15/12/2025 07:07
Dec 15 (Reuters) - Richter Gedeon Nyrt GDRB.BU says in a statement on the Budapest Stock Exchange website: HUNGARY RICHTER SAYS FDA HAS GRANTED 6-MONTH ADDITIONAL EXCLUSIVITY FOR CARIPRAZINE IN THE US THIS EXPIRES 17 MARCH 2030 Source text: [ID:] Further company coverage: GDRB.BU (Reporting by Krisztina Than) ((Krisztina.Than@thomsonreuters.com;))
Recent news on Gedeon Richter
See all newsBrief: Hungary's Richter says US FDA accepted for review its new drug application for Fylrevy
Brief: Hungary's Richter Upgrades 2026 Pharma Clean EBIT Guidance To Double-Digit Growth
development partnership in Tirzepatide
AI in Hungary could unlock productivity gains of €15 billion, McKinsey says
Brief: Hungary's Richter and Hetero announce cooperation for development of semaglutide injection